The term “nootropic peptides” is used to group a handful of compounds that have very little in common beyond their marketing. Some are true peptides with decades of clinical use in one country. Some are synthetic molecules modelled on peptides but not peptides in the usual sense. One is not really a peptide at all. And the evidence behind them ranges from registered-medicine trial programs to a mechanism paper that has since been retracted.
Grouping them under one label hides those differences. A reader comparing Semax and Dihexa as if they belonged to the same evidence category would be comparing human clinical data from Russia with animal-only work whose central mechanism is no longer supported in the literature.
The argument of this post is that each compound needs to be read on its own terms: what it is chemically, what it has been shown to do, in what system, and by whom. The sections below cover Semax, Selank, Dihexa, P021, Epitalon, Pinealon, DSIP and Noopept, with the strength of evidence stated for each.
One Label, Very Different Evidence
| Compound | What it is | A peptide? | Strongest evidence found |
|---|---|---|---|
| Semax | ACTH(4–7) fragment + Pro-Gly-Pro (7 amino acids) | Yes | Human, Russian clinical trials; registered in Russia |
| Selank | Tuftsin + Pro-Gly-Pro (7 amino acids) | Yes | Human, small Russian trials; reported registered in Russia |
| Dihexa | Angiotensin IV–derived peptidomimetic | Peptide-like | Animal only; key mechanism papers retracted |
| P021 | CNTF-derived modified tetrapeptide | Peptide-like | Animal only |
| Epitalon | Synthetic tetrapeptide (Ala-Glu-Asp-Gly) | Yes | Cell culture and animal |
| Pinealon | Synthetic tripeptide (Glu-Asp-Arg) | Yes | Cell culture and rodent |
| DSIP | Nonapeptide | Yes, but origin unclear | Small, conflicting human studies |
| Noopept | N-acyl dipeptide ester prodrug (MW 318) | No, in the usual sense | Small Russian human trials |
Two patterns stand out. Every compound with human data comes from Russian or post-Soviet research programs, with little independent replication elsewhere. And every compound developed outside that system remains at the animal stage.
Semax: An ACTH Fragment Analog
Semax is a synthetic heptapeptide, Met-Glu-His-Phe-Pro-Gly-Pro. It combines a fragment of adrenocorticotropic hormone, ACTH(4–7), with a C-terminal Pro-Gly-Pro tripeptide added for stability (Dmitrieva et al., Cell Mol Neurobiol, 2010). It is designed to lack the hormonal activity of full-length ACTH.
BDNF and TrkB. Its best-characterized mechanism comes from rodent work. A single intranasal application in rats produced a 1.4-fold increase in hippocampal BDNF protein and a 1.6-fold increase in TrkB phosphorylation, alongside increased BDNF and TrkB gene expression (Dolotov et al., Brain Res, 2006). Later rat studies reported activation of neurotrophin and receptor gene transcription after experimental cerebral ischemia.
Human evidence. Semax is registered as a medicine in Russia and appears on the Russian List of Vital and Essential Drugs (RLS drug reference). Its clinical record consists of Russian trials, largely in stroke and cerebrovascular disease, many published in Russian-language journals, including a non-randomized 2018 study that reported changes in plasma BDNF. As of the most recent reviews, no clinical trials have been published outside Russia and post-Soviet states.
Selank: A Tuftsin Analog
Selank is a synthetic heptapeptide, Thr-Lys-Pro-Arg-Pro-Gly-Pro, built on tuftsin, a naturally occurring tetrapeptide fragment of immunoglobulin G with immune-regulatory activity. The same Pro-Gly-Pro extension used in Semax was added for stability (Koroleva and Myasoedov, Biology Bulletin, 2019).
Proposed mechanisms. Animal and in vitro studies have examined Selank’s effects on GABAergic signaling, serotonin metabolism, enkephalin-degrading enzymes and hippocampal gene expression. These are research observations, mostly from the developing institute, and have not been established in humans.
Regulatory status. Selank is reported to have been registered in Russia in 2009, for generalized anxiety disorder and neurasthenia. That registration date and indication are consistent across secondary sources, though the registry entry itself was not located for this post. The clinical studies behind it are small and Russian; the principal comparator trial enrolled 62 patients and compared Selank with a benzodiazepine without a placebo arm, which limits how its results can be interpreted.
Dihexa: A Retracted Mechanism
Dihexa is a small synthetic molecule derived from angiotensin IV, developed at Washington State University. It is often called a peptide but is better described as a peptidomimetic: a modified molecule designed to be stable and brain-penetrant.
The proposed mechanism. Its developers proposed that Dihexa binds hepatocyte growth factor (HGF) and enhances its activation of the c-Met receptor, promoting the formation of new synapses. The key paper making that case, Benoist et al. 2014 in the Journal of Pharmacology and Experimental Therapeutics, received a journal Notice of Concern over possible image manipulation (JPET notice) and was subsequently retracted, as was a related 2012 paper from the same group (PubMed, Kawas et al. 2012, marked retracted). The concerns arose alongside a university investigation of research by a former doctoral student who later led the spin-off company commercializing the work (Retraction Watch).
What that leaves. The HGF/c-Met system is genuine and well-studied neurobiology. What is no longer supported is the specific evidence linking Dihexa to it. The mechanism is unsupported, not disproven. All Dihexa data are from animal and cell studies; no human trials have been conducted. Because c-Met signaling is also a well-characterized driver of tumor growth, the pathway raises safety questions that have not been studied.
P021: A CNTF-Derived Peptidomimetic
P021 (originally named P21) was derived by epitope mapping from the most active region of ciliary neurotrophic factor (CNTF), with an adamantylated glycine added to improve blood–brain barrier penetration and reduce degradation (Baazaoui and Iqbal, Alzheimers Res Ther, 2017). Its sequence is reported as Ac-DGGLAG-NH2.
Research findings. In a series of mouse and rat studies from Khalid Iqbal’s laboratory at the New York State Institute for Basic Research, P021 increased BDNF expression, boosted hippocampal neurogenesis and rescued synaptic and behavioral deficits in transgenic Alzheimer’s-model mice (Kazim et al., Neurobiol Dis, 2014).
The limit. No study has tested P021 in humans (Alzheimer’s Drug Discovery Foundation), and nearly all of its data come from one laboratory. Mouse models of neurodegeneration have a long record of not predicting human results.
Epitalon and Pinealon: Khavinson-Group Short Peptides
Both peptides come from the St. Petersburg bioregulator program, discussed in our post on Khavinson peptide bioregulators.
Epitalon is a synthetic tetrapeptide, Ala-Glu-Asp-Gly, designed from the composition of a pineal gland extract, Epithalamin. Its best-known findings are telomerase activation and telomere elongation in cultured human cells, reported first by its developers (Khavinson et al., 2003) and in 2025 by an independent group that also observed telomere lengthening through an alternative pathway in cancer cell lines (Al-dulaimi et al., Biogerontology, 2025). Developer-group studies also report effects on melatonin rhythms. Its relevance to cognition is indirect: it is a brain-aging and circadian research compound, not one studied for cognitive outcomes in people.
Pinealon is a synthetic tripeptide, Glu-Asp-Arg. In cultured rat cerebellar granule cells, neutrophils and PC12 cells, it reduced reactive oxygen species accumulation in a dose-dependent manner and reduced necrotic cell death under oxidative stress (Khavinson et al., Rejuvenation Res, 2011). Rodent studies from affiliated groups report effects in hypoxia models. The developers propose that short peptides like Pinealon act by binding DNA directly to regulate gene expression, a mechanism outside mainstream pharmacology and not independently confirmed. No human efficacy studies were identified, and claims about mitochondrial function rest on limited data. Mitochondria-targeted compounds with a more developed evidence base are compared in our post on mitochondrial peptides such as MOTS-c and SS-31.
DSIP: A Peptide Without a Gene
Delta sleep-inducing peptide is a nonapeptide, Trp-Ala-Gly-Gly-Asp-Ala-Ser-Gly-Glu, isolated in 1977 from the cerebral venous blood of rabbits in induced sleep. Its name reflects the early finding that it promoted delta-wave EEG activity in recipient animals.
Nearly fifty years on, its basic biology remains unresolved. No gene, precursor protein or specific receptor has been identified, and a 2006 review by researchers who worked extensively on it described DSIP as “a still unresolved riddle” (Kovalzon and Strekalova, J Neurochem, 2006). Human sleep studies from the 1980s and 1990s produced inconsistent results, and the peptide was never developed into an approved medicine in the West. It remains of interest in sleep and stress research, but the original hypothesis behind its name is still not established.
Noopept: Not Really a Peptide
Noopept (N-phenylacetyl-L-prolylglycine ethyl ester, also coded GVS-111) is often sold alongside peptides, but chemically it is a small modified dipeptide derivative with a molecular weight of about 318. Animal studies indicate it acts as a prodrug: it is converted in the body to cycloprolylglycine, an endogenous cyclic dipeptide that has been reported to modulate AMPA receptors and increase BDNF in neuronal cells. Early rat work found the parent compound undetectable in brain an hour after administration, while cycloprolylglycine levels rose (Eur J Drug Metab Pharmacokinet, 1997).
It is registered as a medicine in Russia, while Hungary lists it as a controlled psychoactive substance. Human studies are small and Russian, and it is more accurately grouped with synthetic cognitive-research compounds such as the racetams than with peptides. Its inclusion in “nootropic peptide” lists reflects marketing convention rather than chemistry.
Frequently Asked Questions
Q1: What are nootropic peptides?
Direct Answer: It is an informal marketing label for peptides and peptide-like compounds studied in relation to brain function. It is not a scientific category, and the compounds it covers differ widely in chemistry and evidence.
- True peptides: Semax, Selank, Epitalon, Pinealon, DSIP.
- Peptidomimetics: Dihexa and P021, modified molecules modelled on peptides.
- Not a peptide: Noopept, a small dipeptide-derived prodrug.
Q2: Which of these compounds has human clinical data?
Direct Answer: Semax, Selank, Noopept and DSIP have human studies, all small or regional, and mostly from Russia. Dihexa, P021, Epitalon and Pinealon have no published human efficacy trials of the synthetic compounds.
- Semax: Russian stroke and cerebrovascular trials; registered in Russia.
- Selank: Small Russian trials; reported registered in Russia in 2009.
- DSIP: Older human sleep studies with inconsistent results.
Q3: Was the Dihexa research retracted?
Direct Answer: Yes. The 2014 paper proposing that Dihexa works through HGF/c-Met, and a related 2012 paper from the same group, were retracted after concerns about image manipulation, leaving that mechanism unsupported.
- 2021: Journal issued Notices of Concern on four papers.
- 2025: Two key mechanism papers retracted.
- Status: Animal data only; no human trials.
Q4: Does Semax increase BDNF?
Direct Answer: In rats, a single intranasal application increased hippocampal BDNF protein and TrkB activation. Human evidence is limited to a non-randomized Russian stroke study reporting plasma BDNF changes.
- Rodent data: 1.4-fold BDNF protein and 1.6-fold TrkB phosphorylation increases.
- Human data: Russian, non-randomized, in stroke patients.
- Gap: No trials outside Russia and post-Soviet states.
Q5: Is Noopept a peptide?
Direct Answer: Not in the usual sense. It is a small synthetic dipeptide derivative that acts as a prodrug for cycloprolylglycine, and it is more closely related to racetam-style compounds than to the other peptides listed here.
- Structure: N-phenylacetyl-L-prolylglycine ethyl ester, MW about 318.
- Active form: Converted to cycloprolylglycine in animal studies.
- Status: Registered in Russia; controlled in Hungary.
Q6: Why is DSIP’s mechanism still unclear?
Direct Answer: Because no gene, precursor protein or receptor for DSIP has ever been identified, so researchers cannot confirm how it is produced in the body or what it acts on.
- Discovery: Isolated from rabbit blood in 1977.
- Human findings: Inconsistent across sleep studies.
- Current view: Described in a 2006 review as an unresolved riddle.
What the Category Actually Contains
Read compound by compound, “nootropic peptides” turns out to be three different things. There are true short peptides from the Russian research system, some with registered-medicine status and modest regional clinical records. There are peptide-like molecules from Western academic labs, promising in animals and untested in people, one of them with its central mechanism now resting on retracted work. And there is at least one compound that is not a peptide at all.
The mechanisms these compounds are studied against, including BDNF and TrkB signaling, HGF/c-Met, neurogenesis and oxidative stress, are legitimate targets in cognitive neuroscience research. What the current evidence does not support is treating any of these compounds as established cognitive enhancers, or treating them as interchangeable. Each one has to be evaluated on its own chemistry, its own data and its own limitations.
Ready to Advance Your Research?
Browse our catalog of verified research peptides, sourced and shipped exclusively within Canada. COAs available on request.
Disclaimer: All Peptide Wave products are intended strictly for laboratory research use only. Not approved for, nor intended for, human or veterinary consumption.
